New painkiller may reduce Post-Surgery nausea in women
NCT ID NCT07026162
First seen Jun 13, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This study tested whether the painkiller oliceridine causes less nausea and vomiting than the standard drug sufentanil in women undergoing gynecologic laparoscopic surgery. Ninety-six participants received one of the two drugs during and after surgery. Researchers tracked nausea, vomiting, and side effects for 48 hours after the operation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LAPAROSCOPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oliceridine (also known as TRV130 or Olinvyk)
What this could lead to
If oliceridine works better, it could offer a new option for pain control with less nausea and vomiting after gynecologic surgery.
What could go wrong
This is a small, completed phase 4 trial with only 96 participants. Results may not apply to all patients, and oliceridine may not prove superior to the standard drug sufentanil.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.